Table 3.
Results. ID—internal derangement [34,35]; P—TMJ pain according to ICOP [34,36]; OA—osteoarthritis [34,37]; DDwR—disk displacement with reduction [34,37]; DDworR—disk displacement without reduction [34,37]; DD—degenerative disorders [34,37]; R—rinse; A—administration; HA—hyaluronic acid; CS—corticosteroids; PRP—platelet rich plasma; I-PRF—injectable platelet rich fibrin; PRGF—plasma rich in growth factors *—randomized controlled trial.
| Section 1: Comparative Studies | |||||
|---|---|---|---|---|---|
| Publication Year | First Author | Diagnosis | Intervention | Substance | Comparison Group |
| 2022 | Ghoneim [38] | DDwR | R+A | I-PRF | R * |
| 2021 | Sembronio [39] | ID, OA | R+A | Adipose tissue | R+HA * |
| 2021 | Sembronio [39] | ID, OA | R+A | HA | R+Adipose tissue * |
| 2021 | Karadayi [40] | ID | R+A | I-PRF | R * |
| 2021 | Jacob [41] | DDwR, DDwoR | R+A | PRP | R * |
| 2021 | Jacob [41] | DDwR, DDwoR | R+A | HA | R * |
| 2021 | Singh [42] | ID | R+A | PRP | R * |
| 2020 | Dolwick [43] | P | R+A | CS | R+Placebo * |
| 2020 | Zarate [44] | P | A | Dextrose+Lidocaine | Lidocaine * |
| 2019 | De Riu [45] | DD | R+A | HA | R+Bone marrow * |
| 2019 | De Riu [45] | DD | R+A | Bone marrow | R+HA * |
| 2019 | Yilmaz [46] | ID | A | HA | R+HA * |
| 2019 | Yilmaz [46] | ID | R+A | HA | HA * |
| 2019 | Bergstrand [47] | OA | R+A | HA | R * |
| 2019 | Isacsson [48] | P | A | CS | Placebo * |
| 2019 | Louw [49] | P | A | Dextrose+Lidocaine | Lidocaine * |
| 2019 | Gokçe Kutuk [50] | P | A | HA | CS * |
| 2019 | Gokçe Kutuk [50] | P | A | CS | HA * |
| 2019 | Gokçe Kutuk [50] | P | A | PRP | CS * |
| 2019 | Diaz [51] | P | R+A | CS | R+Placebo * |
| 2018 | Yapici-Yavuz [52] | DDwoR | R+A | CS | R * |
| 2018 | Yapici-Yavuz [52] | DDwoR | R+A | HA | R * |
| 2018 | Yapici-Yavuz [52] | DDwoR | R+A | Tenoxicam | R * |
| 2017 | Ozdamar [53] | ID | R+A | HA | R * |
| 2017 | Gorrela [54] | DDwR, DDwoR | R+A | HA | R * |
| 2017 | Gurung [55] | OA | R+A | HA | R * |
| 2016 | Cömert Kiliç [56] | OA | R+A | CS | R * |
| 2016 | Patel [57] | ID | R+A | HA | R * |
| 2016 | Bouloux [58,59] | P | R+A | CS | R * |
| 2016 | Bouloux [58,59] | P | R+A | HA | R * |
| 2016 | Cömert Kiliç [60] | OA | R+A | PRP | R+HA * |
| 2016 | Korkmaz [61] | DDwR | A | HA | Splint therapy * |
| 2016 | Lam [62] | P | A | Dextrose+Lidocaine | Lidocaine * |
| 2015 | Cömert Kiliç [63] | OA | R+A | PRP | R * |
| 2015 | Hegab [64] | OA | A | HA | PRP * |
| 2015 | Hegab [64] | OA | A | PRP | HA * |
| 2015 | Guarda-Nardini [65] | DD | A | HA | R+HA * |
| 2015 | Sipahi [66] | ID | R+A | Morphine | R+Placebo * |
| 2015 | Sipahi [66] | ID | R+A | Tramadol | R+Placebo * |
| 2014 | Hancı [67] | DDwR | A | PRP | R * |
| 2014 | Tabrizi [68] | ID | R+A | CS | R * |
| 2013 | Bustaman [69] | OA | A | HA | Placebo * |
| 2012 | Guarda-Nardini [70] | DD | R+A | HA | HA* |
| 2012 | Daif [71] | ID | A | Ozone gas | Oral drugs * |
| 2012 | Guarda-Nardini [72] | DD | R+A | HA | HA * |
| 2012 | Manfredini [73] | DD | R+A | CS | R * |
| 2012 | Manfredini [73] | DD | R+A | HA | R * |
| 2012 | Huddleston Slater [74] | P | R+A | CS | R * |
| Section 2: before-and-after studies | |||||
| Publication | First author | Diagnosis | Intervention | Substance | |
| 2020 | Singh [75] | OA | A | CS+HA | |
| 2020 | Sikora [6] | P | A | HA | |
| 2019 | Giacomello [76] | OA | A | PRGF | |
| 2014 | Pihut [77] | P | A | PRP | |